Flightpath Biosciences

Developer of antibiotic therapies designed to treat pathogen-driven diseases. The company’s therapies kill co-infectious bacteria in Lyme disease and limit microbiome damage and treat multiple pathogenic bacteria in both the oral and gut microbiome, enabling patients to get a new form of a therapeutic treatment to eradicate rare infectious diseases.